FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

LUPIN Consensus Forecast

No. of reports in last year
7
No. of analysts
3
Average Consensus Forecast
1255.29
Consensus Potential
5.60%

LUPIN Price Target Potential

BrokerageTargetPotential
Prabhudas Lilladher131410.24%
Sharekhan135012.63%
Axis Direct12253.72%

LUPIN Targets in FrontPage Forums

17 Users have submitted 17 trade ideas of Rs. 1,035,523.1 for LUPIN
100% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

LUPIN Ratings

Long term LUPIN rating by FrontPage users
3.3/5 (8 Ratings)

7 LUPIN share price target reports by brokerages below. See what is analyst's view on LUPIN share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. LUPIN Forum
  3. LUPIN Price Target

LUPIN Share Price Target

LUPIN Share Price Target - Broker Reports - 2021

15-Jun-21
Price @ Call: 1186.65
Target: 1314
ACCUMULATE
14-May-21
Price @ Call: 1201.85
Target: 1314
ACCUMULATE
25-Jan-21
Price @ Call: 1087.91
Target: 1350
BUY
29-Jan-21
Price @ Call: 999.1
Target: 1287
BUY
12-Jan-21
Price @ Call: 1066.3
Target: 1225
BUY

LUPIN Share Price Target - Broker Reports - 2020

6-Nov-20
Price @ Call: 924.89
Target: 1212
BUY
30-Sep-20
Price @ Call: 995
Target: 1085
BUY
30-May-20
Price @ Call: 860.99
Target: 1001
BUY
We expect US business to get back on track and lead the growth for LPC over FY20-22E due to 1) resolution of Somerset, Goa and Pithampur (Unit-2) in FY21E 2) early launch of Albuterol 3) ramp up of Levothyroxyn 4) launch of complex injectables, Biosimilar and Spiriva in FY22E. LPC guided for EBITDA margin of 18-20% for FY21-22E, which we believe is achievable as LPC has lowered its R&D guidance to 9% of sales (earlier 11-12%), completed remediation work for plants under WL and divested lower margin business (Kyowa). With 14% QoQ growth in Q4FY20 for US, we expect this momentum to continue and US revenues to grow at 10% in FY21E and 15% in FY22E. We have increased our TP to Rs1001 (earlier Rs978) due to marginal change in tax rate assumption, as guided by LPC. We assign 24x PE on FY22E and maintain our BUY rating.
... Read more
10-May-20
Price @ Call: 828.62
Target: 978
BUY
7-Feb-20
Price @ Call: 720.5
Target: 654
REDUCE
While LPC guided for ramp up in Levothyroxyn supply from December CY19, launches of Albuterol (gProAir) in 1HFY21E and injectables in US along with Fostair and Etanercept in EU in H2FY21E and FY22E, we expect lack of control on overheads will percolate lesser benefits in earnings. R&D guided to be around 10% and has possibility of flare up than guided range due to trials of key generics. The status of four plants continues to be under OAI status and new observations in Nagpur (formulations) plant continues to be strong overhang in valuation due to adverse risk-return matrix. With manufacturing issues (FDA) in key plants, there are likely to be delayed approval in complex generics. We have reduced our earnings estimates by 32% in FY21E and 26% in FY22E due to delayed launches in US, slower ramp- up in Levothyroxyn and divestment of Kyowa. We have downgraded our recommendation to ‘Reduce’ from ‘Hold’. We also roll forward to FY22E and derive our new TP of Rs653 (previous TP of Rs760) on PE 20x (earlier 19.5x) of FY22E.
... Read more

LUPIN Share Price Target - Broker Reports - 2019

12-Nov-19
Price @ Call: 731.45
Target: 860
BUY
We cut our EPS estimate for FY21 by only 2% to INR37.8 as the decrease in EBITDA due to the sale of the Kyowa business is likely to be largely offset by lower depreciation/interest cost. We continue valuing LPC at 21x 12m forward earnings to arrive at a price target of INR860. We remain positive on LPC, given its healthy ANDA pipeline for the US market, limited price erosion in the US base business and the steady outperformance in the domestic formulation market. Maintain Buy.
... Read more
26-Nov-19
Price @ Call: 799.36
Target: 824
ACCUMULATE
Lupin, which was founded in 1968 by Shri Desh Bandhu Gupta, is currently the fifth largest company in Indian Pharmaceutical Market and fourth largest by prescription volume in the US. We initiate coverage on Lupin with an Accumulate rating and a target price of Rs824 based on 20x FY22E earnings. FY20 base earnings (ex Ranexa) stand at around Rs 21 per share.
... Read more
13-Nov-19
Price @ Call: 737.25
Target: 760
HOLD
The sell-off of Kyowa at 1.8x EV/EBITDA is at justifiably lower valuation (vs. peer deals) due to inertia in Japan generic business. While the sell-off to increase concentration risk with higher contribution from US and India, there could be better option to deploy new capital (sourced from the divestment) in focused market. The efficient use of the capital may likely to increase profitability, return ratios and decrease leverage (to 0.08 fro, 0.32). With an opportunity of efficient capital allocation, there could be likely improvementin quality of earnings. We upgrade our recommendation to ‘Hold’ from ‘Reduce’ and increase TP to 760 (from Rs730) with 19.5x of FY21E.
... Read more
6-Nov-19
Price @ Call: 764.92
Target: 730
REDUCE
While LPC guided for ramp up in Levothyroxyn supply and launches of injectables and gProAir (Albuterol) in US along with Fostair and Etanercept in EU in H2FY20E and FY21E, we expect lack of control on overheads will percolate lesser benefits in earnings. R&D guided to be around 10% and has possibility of flare up than guided range due to trials of key generics. The status of four plants in OAI continues to be a strong overhang in valuation due to adverse risk-return matrix. We maintain ‘Reduce’ recommendation and retain TP at Rs730.
... Read more
8-Aug-19
Price @ Call: 765.18
Target: 861
HOLD
We downgrade our revenue estimates for FY20E/FY21E by 3.7%/1.5% respectively on account of downgrade in US, Europe and other markets. We upgrade our EBITDA margin by 20 bps /80 bps to 18.9%/20% for FY20E /FY21E due to lower staff expenses, other expenses and R & D. We downgrade our EPS estimates by 8.2% for FY20E to Rs 28.3 and broadly maintain our EPS estimates for FY21E at Rs 41.1. We maintain our HOLD rating on the stock with a price target of Rs 861 based on 21x FY21E.
... Read more
9-Aug-19
Price @ Call: 761.2
Target: 730
REDUCE
Q1 in line; Key markets lack positive surprises
We believe that high concentration of revenues from key drugs such as gRanexa and Levothyroxin may be short-lived, given that FDA’s newstrategy of faster approvals led to reduce the longevity of complex genericsto few months. LPC’s dependence on fewer generics for its growth in USwould like to continue and render its risk-return matrix unfavorable. While R&D is guided to be limited at 10% of sales, there are possibilities of higher R&D costs due to larger clinical trials of inhalers, complex injectables and specialty products in US. We maintain ‘REDUCE’ rating and TP at Rs730.
... Read more
19-Jul-19
Price @ Call: 756
Target: 900
BUY
Outlook and valuation: Limited downside; maintain ‘BUY’ The stock’s current valuation of 17.5x FY21E EPS – amid depressed earnings – offers an attractive entry in our view. Encouraging respiratory and biosimilar franchise may unlock value in the long run. We maintain ‘BUY/SP’ with a TP of INR900.
... Read more
16-May-19
Price @ Call: 762.25
Target: 715
REDUCE
Cutting down our earnings estimates by 35.9%/28.6% for FY20E and FY21E to factor in lower than expected 4QFY19, USFDA regulatory concerns and higher tax rates. We downgrade our recommendation to Reduce from earlier HOLD recommendation with a revised Target Price of Rs715 (from Rs803 earlier).
... Read more
17-May-19
Price @ Call: 781.35
Target: 930
BUY
We maintain a BUY on LPC following in line operational performance in 4QFY19. Our TP is revised at Rs 930/sh (22x FY21E EPS) following a 10% cut in our FY21E EPS to account for higher tax and slower ramp up in Solosec.Despite being marred by repeated US FDA issues, LPC’s visible levers for both revenue and profitability help maintain our positive stance. India franchise, valued at ~Rs 650/sh, continues to protect the downside risk.
... Read more
16-May-19
Price @ Call: 783.1
Target: 861
HOLD
We downgrade our revenue estimates by 2.8 %/1.1% for FY20E/FY21E on account of downgrade in India, US and API. We downgrade our EBITDA margin by 120 bps /70 bps for FY20E /FY21E due to higher staff cost, overheads and R & D. We downgrade our EPS by 20.9%/4.5% to Rs 30.8/ Rs 41 for FY20E/FY21E respectively. We downgrade our price target to Rs 861 based on 21x FY20E and maintain our HOLD rating on the stock.
... Read more
16-May-19
Price @ Call: 783.1
Target: 810
HOLD
According to the management’s assertion, the macro situation in the USgenerics space is on the mend with overall price erosion stabilising at low single digit. For FY20, it has guided for 20+ launches including key launches. However, the resolution of warning letter and clearance of Official Action Indicated (OAIs) status on plants could be a near term overhang along with progress on the margins front. Growth in India remains consistent but remains lumpy for APAC (mainly Japan). Like other pharma majors, Lupin has also chalked out a product and cost rationalisation drive. The result of this drive could be visible two to three years down the line. We arrive at our target price of | 810 based on 20x FY21E EPS of Rs 40.4.
... Read more
16-May-19
Price @ Call: 783.1
Target: 730
REDUCE
We cut our FY20/21E estimates by 14-15% as we trim our EBIDTA margins to 15% vs 17% earlier due to weak consumption demand outlook in the near term. IGPL with 53,000MT capacities coming on stream by end of CY19 is set to be the third largest PAN player globally. Maintain BUY with a PT of Rs477 (Rs530 earlier) as we value IGPL at 6x EV/E or 10x PER FY21E. Maintain Buy
... Read more
24-Apr-19
Price @ Call: 856.01
Target: 840
REDUCE
25-Apr-19
Price @ Call: 865.92
Target: 800
SELL
11-Feb-19
Price @ Call: 818.38
Target: 985
BUY
8-Feb-19
Price @ Call: 821.75
Target: 840
HOLD
8-Feb-19
Price @ Call: 821.75
Target: 850
HOLD
7-Feb-19
Price @ Call: 841.95
Target: 1000
BUY

LUPIN Share Price Target - Broker Reports - 2018

31-Oct-18
Price @ Call: 889.02
Target: 713
REDUCE
10-Aug-18
Price @ Call: 820.75
Target: 950
BUY
10-Aug-18
Price @ Call: 827.95
Target: 727
REDUCE
26-Jul-18
Price @ Call: 800
Target: 920
BUY
17-May-18
Price @ Call: 761.01
Target: 930
BUY
17-May-18
Price @ Call: 766.75
Target: 665
SELL
16-May-18
Price @ Call: 750.85
Target: 865
BUY
16-May-18
Price @ Call: 750.85
Target: 727
REDUCE
16-May-18
Price @ Call: 750.85
Target: 780
HOLD
15-Mar-18
Price @ Call: 786.62
Target: 830
HOLD
7-Feb-18
Price @ Call: 801.65
Target: 940
BUY

LUPIN Share Price Target - Broker Reports - 2017

13-Nov-17
Price @ Call: 831.84
Target: 1140
BUY
9-Nov-17
Price @ Call: 842.55
Target: 1050
HOLD
8-Nov-17
Price @ Call: 860.5
Target: 1000
BUY
3-Nov-17
Price @ Call: 1053.63
Target: 1565
BUY
31-Oct-17
Price @ Call: 1027.55
Target: 1187
BUY
31-Oct-17
Price @ Call: 1027.55
Target: 1105
HOLD
31-Oct-17
Price @ Call: 1027.55
Target: 1215
BUY
12-Oct-17
Price @ Call: 1045.5
Target: 1280
BUY
12-Oct-17
Price @ Call: 1045.5
Target: 1215
BUY
21-Sep-17
Price @ Call: 1002.2
Target: 1125
BUY
3-Aug-17
Price @ Call: 995
Target: 1169
BUY
7-Aug-17
Price @ Call: 993
Target: 1467
BUY
4-Aug-17
Price @ Call: 995
Target: 1125
BUY
4-Aug-17
Price @ Call: 993
Target: 1650
BUY
3-Aug-17
Price @ Call: 993
Target: 1010
HOLD
18-Jul-17
Price @ Call: 1156
Target: 1170
HOLD
10-Jul-17
Price @ Call: 1135
Target: 1650
BUY
25-May-17
Price @ Call: 1140
Target: 1335
BUY
25-May-17
Price @ Call: 1228
Target: 1800
BUY
9-Feb-17
Price @ Call: 1491
Target: 1880
BUY
9-Feb-17
Price @ Call: 1490
Target: 1850
BUY
13-Feb-17
Price @ Call: 1490
Target: 1771
BUY
15-Feb-17
Price @ Call: 1435.31
Target: 1600
HOLD
10-Feb-17
Price @ Call: 1495
Target: 1730
ACCUMULATE
10-Feb-17
Price @ Call: 1478
Target: 1760
BUY
9-Feb-17
Price @ Call: 1491.35
Target: 1660
HOLD
10-Feb-17
Price @ Call: 1495
Target: 1730
BUY

LUPIN Share Price Target - Broker Reports - 2016

20-May-16
Price @ Call: 1539.05
Target: 1660
HOLD
27-Dec-16
Price @ Call: 1405
Target: 1667
BUY
10-Aug-16
Price @ Call: 1566.95
Target: 1804
BUY
10-Nov-16
Price @ Call: 1529
Target: 1890
BUY
10-Nov-16
Price @ Call: 1529
Target: 1769
BUY
7-Nov-16
Price @ Call: 1421
Target: 1650
ACCUMULATE
14-Oct-16
Price @ Call: 1465.75
Target: 2040
BUY
25-Aug-16
Price @ Call: 1531.75
Target: 1650
ACCUMULATE
10-Aug-16
Price @ Call: 1608
Target: 1800
BUY
11-Aug-16
Price @ Call: 1569.5
Target: 1831
BUY
12-Jul-16
Price @ Call: 1672.1
Target: 1900
HOLD
29-Jun-16
Price @ Call: 1430
Target: 1693
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • LUPIN Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 31,196.07
    Upside Target 21,191.03
    Upside Target 11,186.12
    Pivot1,181.08
    Downside Target 11,176.17
    Downside Target 21,171.13
    Downside Target 31,166.22
  • LUPIN Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 31,218.05
    Upside Target 21,204.8
    Upside Target 11,193
    Pivot1,179.75
    Downside Target 11,167.95
    Downside Target 21,154.7
    Downside Target 31,142.9
  • LUPIN Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 31,370.35
    Upside Target 21,319
    Upside Target 11,234.05
    Pivot1,182.7
    Downside Target 11,097.75
    Downside Target 21,046.4
    Downside Target 3961.45
  • LUPIN Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 31,191.03
    Upside Target 21,187.23
    Upside Target 11,184.88
    Pivot1,181.08
    Downside Target 11,177.28
    Downside Target 21,174.93
    Downside Target 31,171.13
  • LUPIN Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 31,204.8
    Upside Target 21,195.23
    Upside Target 11,189.32
    Pivot1,179.75
    Downside Target 11,170.18
    Downside Target 21,164.27
    Downside Target 31,154.7
  • LUPIN Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 31,319
    Upside Target 21,266.93
    Upside Target 11,234.77
    Pivot1,182.7
    Downside Target 11,130.63
    Downside Target 21,098.47
    Downside Target 31,046.4
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020